Star Therapeutics is a biopharmaceutical company focused on developing life-changing therapies for rare diseases. They aim to address the unmet need for treatments for the millions of patients suffering from rare conditions. Their portfolio includes first-in-class antibody therapeutics built on novel biology.

Star Therapeutics

Star Therapeutics is a biotechnology company with a mission to develop life-changing therapies for as many rare diseases as possible for the millions of patients in urgent need. Our innovation engine starts with identifying multiple rare diseases that share a common biology and then discovering novel therapeutics that can treat these diseases with a single therapy. Star consists of a family of companies, each focusing on a specific area of novel biology and developing first-in-class antibody therapeutics. Electra Therapeutics, the first company within our portfolio to be unveiled, is developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer. 

Westlake Village BioPartners

Cormorant Asset Management

Cowen Healthcare Investments

New Leaf Venture Partners

OrbiMed

RA Capital Management

Redmile Group

Our CEO, Adam Rosenthal, shares the origin story and mission of Star Therapeutics. We look at the “the long tail of disease”, the thousands of rare diseases with inadequate treatment, and see limitless opportunities to make an impact.
#UniverseOfPossbilities

Star is applying expertise in rare diseases and antibody drug discovery to advance drug programs that target multiple diseases with a single therapy.
#UniverseOfPossibilities

Star Therapeutics emerges from stealth mode raising $100M in financing since inception to be an innovation engine for rare disease therapies.
#UniverseOfPossbilities

Introducing Star Therapeutics. Our sights are set on developing life-changing therapies for as many rare diseases as possible for the millions of patients globally.
#UniverseOfPossibilities

COM:STAR-THERAPEUTICS

Star Therapeutics